From: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
 | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
Variable | Â | HR (95% CI) | P value | HR (95% CI) | P value |
CSRN | – | 1.000 |  | 1.000 |  |
+ | 2.203 (1.253–3.873) | 0.006 | 2.017 (1.130–3.599) | 0.018 | |
Age | <  70 | 1.000 |  |  |  |
≥ 70 | 1.690 (0.926–3.085) | 0.088 |  |  | |
Body weight (kg) | <  60 | 1.000 |  |  |  |
≥ 60 | 1.130 (0.652–1.960) | 0.663 |  |  | |
Barcelona Clinic Liver Cancer stage | B | 1.000 | Â | Â | Â |
C | 1.071 (0.616–1.861) | 0.808 |  |  | |
Up to seven | In | 1.000 | Â | Â | Â |
Out | 1.450 (0.838–2.510) | 0.184 |  |  | |
Metastatic disease | – | 1.000 |  |  |  |
+ | 1.042 (0.576–1.886) | 0.891 |  |  | |
Previous therapy: Transcatheter treatment | – | 1.000 |  |  |  |
+ | 1.203 (0.650–2.229) | 0.556 |  |  | |
Refractory to Transcatheter treatment | – |  |  |  |  |
+ | 1.311 (0.596–1.520) | 0.742 |  |  | |
α-fetoprotein (ng/mL) | <  400 | 1.000 |  |  |  |
≥ 400 | 1.630 (0.920–2.885) | 0.094 |  |  | |
Albumin | ≥ 3.2 | 1.000 |  | 1.000 |  |
 | <  3.2 | 2.866 (1.309–6.276) | 0.008 | 2.401 (1.073–5.370) | 0.033 |